Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4]
Titel:
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4]
Auteur:
Ocio, Enrique Perrot, Aurore Bories, Pierre San-Miguel, Jesús F. Blau, Igor W. Karlin, Lionel Martínez-López, Joaquín Pönisch, Wolfram Bringhen, Sara Marcatti, Magda Mateos, María-Victoria Rodríguez-Otero, Paula LeRoux, Nadia Dong, Yvonne Macé, Sandrine Fitzmaurice, Thomas Moreau, Philippe